Overview

Safety and Tolerability of QVA149 (Indacaterol/Glycopyrrolate) Compared to Placebo and to Indacaterol in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)

Status:
Completed

Trial end date:
2008-07-01

Target enrollment:

Participant gender:

Summary

An investigational inhalation product (QVA149) for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD) is being developed. This 14 day study will investigate the effect on heart rate and cardiovascular effects to ensure the product is safe.

Phase:

Phase 2

Details

Lead Sponsor:

Novartis

Treatments:

Glycopyrrolate